Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is a step in the right direction. Thanks GG, I think that was a great interview. I feel better just knowing they are making the effort.
The point is to get everyone as excited as we are about the technology. At this stage, I am encouraged that we will get out of this funk if they continue to keep telling the story.
It is important to me that there is an effort being made. I think that the whole world has been waiting for a discovery such as Recaf, so there shouldn't be any problem informing the scientific community and the public at large how we will transform the way doctor's will practice medicine in the very near future. Most people feel that it could only be science fiction or it will be years away (like stem cell research) before it will available.
There probably isn't one person on this board or anyone in the world who wouldn't want to be tested for cancer just for piece of mind. I am pleased to see that Terry did a great job and can only hope that he continues on this path instead of Wittenberg's penny rags. Good job Terry. I hope you will be hearing from Quest Diagnostics very soon. Stay close to the phone. I would be shocked if they aren't interested in finding more about Recaf. I'll check in with you next week.
I don't know nor will I pretend to know what is going on behind closed doors. What I do know is that I'm ready to do what is necessary to get us noticed after 4 years of waiting. The faster we get this information into the right hands the faster I retire.
I will follow up with this individual early next week and give everyone an update (unlike management).
Good news to all longs. I just had a conversation with someone from Quest Diagnostics and he has a strong background in the cancer marker field and had no idea about our company, but was excited with what I showed him. He was baffled why he had never heard about us before. He is eager to do his homework on the company and he feels he would be a hero to the company if what I was telling him about was all true. If Quest is our final licensing agreement don't thank Wittenberg, thank me. I would be very surprised if they don't contact BioCurex very soon, because I explained about the semi-exclusivity of the licensing agreement.
I'll continue to do what I have to.
Gold, you were the one who opened my eyes to Wittenberg. I have always said Dr Moro is a hero to me and has done nothing wrong, but he fails to put friendship aside and spend shareholder money on the proper and logical expenses that would benefit all of us. We need an experienced biotech CEO, CFO, and a media relations dept. to put out regularly scheduled updates.
There were millions of shares squandered and money spent on embarassing penny newsletters that showed desperation, because they are unwilling to get the right experienced managers. Failure will lead to more failure and success will lead to further success.
There is no magic to this formula. I would consider how they disregard shareholders borders on malice. How can anyone justify the share price when there is no attempt by management to communicate PROPERLY to shareholders directly. Their website is outdated with projections from 2002. I feel we could have taken the high road we are ready to contact IBD, Wall Street Journal, Forbes or any number of legitimate publications on our progress in capitalizing on the only universal cancer marker. The investment world has a right and needs to know. Every day I hear about new discoveries and hopeful therapies. Why has no one heard of BioCurex? I'm not changing my mind on the technology, but I feel helpless by Dr Moro's failure to act now to do something about it.
Ted, you need to right, but management can care less about its shareholders. That is evident by no update in over 8 months. It is dispicable. We have to get new management.
Why aren't we presenting at more conferences? Look at what Dr Moro said in the last press release.
After the presentation Ricardo Moro, President and CEO of BioCurex stated, “These presentations to the ISOBM validate our joint efforts to develop the RECAF assay in the chemoluminescence format used by high throughput automated instruments. These results correlate with those in previous presentations and provide additional support for the effectiveness of the RECAF technology. This presentation will, no doubt, trigger a positive response from the scientific community and demonstrates to our shareholders that we are steadily progressing toward the commercialization of the technology.”
The company has set the lofty goal of gaining a minimum of 25% market share within the next 5 years, with the hopes that their RECAF products will replace most other tests on the market. These aspirations may not be hard to accomplish since RECAF has been proven to detect all cancers with 90% sensitivity. The company is well positioned with two of the biggest companies in the industry and looks forward to the not so distant future.
He says, "this presentation will, no doubt, trigger a positive response from the scientific community........".
Let's get the word out. It's time for new management and an itinerary for the shareholders that lays out the company's goals, and a projected timeline and efforts put forth to attain those goals. This company is a failure at communication, and I am finally admitting I shouldn't be so surprised at the share price, because no one has any idea if we are weeks, months or years away.
We need an investor update and new management.
Down 10% on 4000 shares.
You brought up a rational answer as to why the share price didn't fly after the announcement. They made a deal with the devil and they don't want to pony up 4 million dollars that they are obligated to do. Also, they have all of are assets including our patents for collatoral which was not a brilliant move if you ask me. They are purposely holding downthe share price. Maybe they don't have an extra 4 million laying around.
550 down on the TSX equates to what percentage? I wish we had invented anticoagulants, because my portfolio is hemorrhaging big time.
Tomorrow is going to be an ugly day on Wall Street. I saw the futures were at max down. Most world markets are down at least 5% today. We may open down 400(+). Biocurex is the only stock that can cover my losses in my other stocks. We will see capitulation which is what the market needed to wash out the rest of the wary investors. It has been a very frustrating start to the new year to say the least. Apple is reporting tomorrow after the bell and they will beat the steet handily, but the street will be listening closely to their comments on future earnings. I'm pretty nervous about tomorrow.
4.50-5.00 is where we should be today without a buyout. Dr Moro is giving his life to finding a cure. It is not about the money to him. I know he came here from Uraguay with humble beginnings and he probably feels he is blessed with what he has now materially, but his legacy will not be to devote his life and stop just short of curing mankind of cancer. He is so confident if you ever had a chance to talk with him. IMO, I would like BioCurex to take the lead and learn from Inverness and buy out Combupharma. They have been using Recaf to find a cure and say they are already in trials. What about our patent if he does not buy them? That was a question I posed and never got an answer back from Terry, because he is not privy to all that is going on.
Dr Moro will not sell at this time or if he considered it he would divide the company and sell part of it. It is only in the best interest of Inverness to buy now before there are any definitive earnings. The market cap now is a paultry 28 million dollars. We will have earnings estimated at several hundred million dollars. I looked at every deal they did and on average they were paid in stock or cash the equivalent of about 6 times their market cap. That would value the deal at around 200 million. NO WAY will he sell out now. That would value us at about 4.50-5.00 a share.
Th last shareholder update was May 2007. I think it would be appropriate to comment to the shareholders directly on a quarterly basis. It has been over 8 months since their last update. Put down the suction and the forceps and earn your millions of shares you think you deserve.
There are definitely only 3 licences available. We could not have partnered with anyone better than Inverness. They are polar opposites of Abbott. Abbott has been slower than s***, and Inverness goes back to our roots of Whispering Oaks, because they are like a race horse. We do not have any exclusivity when it comes to the rapid test.
I think Dr Moro is much more eager to get the rapid test out because there were projected sales of several hundred million worldwide and we will get a few dollars on each test sold. Don't forget that we will not and cannot have any competition, because we have discovered the only universal cancer marker.
Abbott is working on a cancer test with Recaf for lung cancer first, because they are trying to fill a void. The more I read up on Inverness and the companies they purchased, the more I realize how valuable our technology is to them.
Remember I was told Inverness was totally blown away with the results they independantly obtained in their facility. Now it is more important than ever that management seize this opportunity and capitalizes on the announcement of this deal. They have to get us Real news coverage. If Inverness wants to play like that we have to counteract. If I was in charge (unlike Wittenberg) I would contact the remaining top tier diagnostics companies PERSONALLY and tell them they have one last chance to be the final licensee before they will lose 100's of millions of dollars in sales to Abbott and Inverness, because there is only one contract remaining and they will be locked out from obtaining exclusive rights to the only universal cancer marker discovered! The last deal should be the sweeetest deal we make. We are holding 4 aces right now.
There is definitely a strategy to them not discussing our company with anyone. I finally just took the time to go to the Inverness website and there is no way they want only a semi-exclusive deal. It is killing them right now that we haven't conceded.
Kag, I think I have an answer. Previously I was hearing thoughts of a buyout. I think the odds are extremely high that Inverness is not giving any competitors any reason to look at BioCurex, so they can add us to their aggressive list of acquisitions.
Look at this mindblowing shopping spree by Inverness in the last 12 months alone:
14 acquisitions:
Medox Chemicals
Promeson
First Check Diagnostics
Benelux Distributors Orange Medical
Biosite
Cholestech
Panbrio Limited
Alere Medical
Paridigm Health
BBI Holdings
Matritech
Redwood Toxicology Lab
Let's all get real. I had no idea how aggressive they were. Every deal they ever made is published on their website.....EXCEPT.....you guessed it.......Biocurex. I am probably buying more of our stock, because it appears there is a definite pattern. Inverness will want the whole pie and not just a piece. I hope Dr Moro divides the company as he said he would 4 years ago, he sells off the diagnostics and he buys Combupharma and takes over on the therapy side to speed up the treatment of cancer.
I think that Inverness is so heavily followed it would cost them big bucks if they let on to them doing a deal with BioCurex.
This was probably a bigger deal than any of us realized. I am glad I held on and IMO I expect we will be bought shortly. I didn't see it till I just went to their website and looked for a press release on us and didn't see one, but I have never seen a company this agressive to buy 14 companies in ONE year. The question is will Dr Moro let it happen?
The issue is with who is selling Recaf. It is all about presentation. You have to be able to come across as if this is the most important discovery in cancer history. There should be a line out the door of Dr Moro's office, news reporters everywhere tracking the progress on this, and Dr Moro should be a rock star right now.
I agree. I think in retrospect, the negotiations should have been for a several million dollar upfront fee. This would have allowed us to avoid toxic funding and further dilution. It would also have caused Abbott to get this to the market much sooner. When I look at the doctors involved with our company, past and present, it is the most knowledgeable modern medicine has to offer.
I was told that not only did they like what they saw, but they were totally "blown away" by the results they got from their blind studies in THEIR facility.
I have to remind myself every once in a while why I have stuck by this company thru thick and thin. This may help everyone clear their heads and reassure them that what we have invested in is truly a remarkable discovery:
Cancer Markers
Cancer markers allow one to distinguish cancer cells from non-cancerous cells. An ideal cancer marker is a molecule present in all cancer cells but not in normal or benign tumor cells. This ideal has yet to be fulfilled: None of the best cancer markers - AFP, CEA, PSA and Ca125- are very sensitive (they are not always expressed in cancer cells), they are restricted to certain organs (liver/testis, colon/rectum, prostate and ovary respectively). Moreover, in many cases they are not cancer specific (benign tumors might also express them). The following excerpts (edited for clarity) illustrate the point:
CEA: From Oncolink, University of Pennsylvania, Cancer Center, Feb 2001.
Carcinoembryonic antigen (CEA) is a protein normally found in very small levels in the blood of healthy people, but may become elevated in some people who have cancer or benign conditions. ...cigarette smokers, and patients with disorders such as ulcerative colitis, liver disease, and lung infection also may have elevated CEA levels."
PSA: From the library of the North Memorial Health Care in Minnesota, (March 2001.)
"Only one-third of all men with a circulating PSA (Prostate Specific Antigen) greater than a certain value (4.0 ng/ml) will actually be found to have cancer on subsequent biopsy. Most will have simple hypertrophy, prostatitis, or other benign conditions. By increasing the cut-off (to 10 ng/ml), the fraction of men with cancer grows to two-thirds, but in over half of those patients, the tumor will have already spread beyond the prostate gland, rendering it surgically incurable. In order to become a clinically effective tool for the detection of early, potentially curable prostate cancer, the specificity of PSA needs to be improved."
CA125: From Oncolink, University of Pennsylvania, Cancer Center, Feb 2001.
"Unfortunately, people without cancer demonstrate a large variation in levels of CA 125 making the determination of what is normal difficult. In general women under 50 years of age have higher levels than women over 50 or men. The finding of elevated CA 125 was noted to be elevated in a number of benign conditions including infections, and endometriosis. Because of this, CA 125 levels are not used as a screening test to find unknown cancer but rather to follow the progress of documented cancer."
Our Technology: RECAF™
The main feature characterizing Recaf is that it is found on many different types of cancer but not on normal or benign tumor cells (e.g. breast fibro-adenomas). Our data shows that cancers of the breast, lung, stomach, prostate express this molecule. In other words, RECAF is present in more than one tissue type. The marker is not only present on the surface and inside cancer cells, but is also found in the blood of cancer patients. As a widespread cancer marker, RECAF could REPLACE those markers which are only available for one type of cancer or which are not sensitive or specific for a malignancy. More importantly, the prevalence of RECAF means that it can be applied to cancers for which there are no other effective cancer markers, such as breast and lung which combined represent 30% of all cancers.
Our day will come, but how fast and how big of a company is the responsibility of management. That is my biggest concern. We are all in agreement that management has disappointed us. They must stop using shareholder money on what continues to be a futile waste. We need new management NOW. We are building the foundation for this company at this very moment and we need the very best experienced leadership. I will say it every day if I have to.
In the Matritech deal they received 6 1/2 times their market cap (total 38 million dollars received for a less than 6 million dollar market cap company). That would give us about 4.50 a share.
However, the extreme difference is that they were a one trick pony....bladder cancer. We have so much more potential being that we have the only universal cancer marker. I'm not even sure how reliable that test is. It was already approved for point of care by the FDA when Inverness bought the company. We may be able to use their model and timeline to figure out where we stand in regards to Recaf point of care testing.
Just this morning, I received news of a client with breast cancer and will undergo double mastectomy. It breaks my heart that this could have been averted if Recaf was on the market. I didn't even want to bring this up to her, because it would only cause anger added to her grief.
It should illegal. What would his motivation to change option price be? That is exactly why the CFO at Broadcom, United Health Care, Adelphia Communications, and a few others are sentenced to jail. I was unaware of this. Just when I think we have all the dirt on Wittenberg's past misdeeds he is continuing to sabatoge us further. Dr Moro PLEASE salvage this company before he takes this ship down and your dreams with it. I will try to email BioCurex in regards to what has been a major disappointment for me as an investor. I was told you, Antonia, Wittenberg, and I know Terry read this board. I'm not venting. I feel you are totally out of touch with shareholders, and as a major shareholder you will listen to my concerns. 4 1/2 years later, we have 2 major licensees, a proven blockbuster, lifechanging discovery and a stock trading a few thousand shares a day at .70 cents. It is illogical.
We need a new management team. I heard Carl Icahn (billionaire investor) on CNBC yesterday say his formula is to take great companies which have bad management and he replaces them with the best leaders and he has consistently been able to immediately genererate hundreds of millions in revenue. His success is attributed to fixing broken management. He attests he is not the reason for the company's turnaround, but replacing poor managers will get your company noticed and get things done. We have no credibility till we have a real CFO and CEO. This is a committment that requires total dedication. Wittenberg treats this like a side job. I am willing to get enough shareholders to force change. This is not a .70 cent stock. This is a 10 dollar stock. There is total lack of communication. Where is the common sense? The stock market is losing billions, because of lack of transparency due to the housing market. This is what is happening at BioCurex. There is no transparency as far as the future of the company.
2008 is time for change. Spend the money on a CEO. The millions lost in market, because of Wittenberg will come back to us 10 times over.
yes, if they do a reverse split 50:1
Looks like shazam worked Dr Wittenberg. We trade 200 shares today. Keep up the great work. We are very pleased with your progress.
I feel like I already have a job there. Only problem is that I don't want it, and I shouldn't have it. Frustration is back again.
I have seen this movie too many times before. It has the same ending everytime. Let's get some new people in the mix (a new board) and rewrite the script, and this time we'll have a happy ending. My patience is wearing thin. There is no getting thru to them on the importance of investors relations.
We are a penny stock because of dilution. When they wake up to the free press, which in my opinion comes across unbiased, we will get investors not daytraders. Here we go again. Dr Moro you and the scientific board are the best at what you do, now surround yourself with management that is competent. I speak for everyone when I say if you don't do something soon your credibility with shareholders will erode. That is your only weak link that has been prohibiting this company from getting its just do. You have to take the reigns and make an executive decision to get new management which will in the long run benefit yourself, the board, and shareholders. Please remove your last obstacle, when you do you'll wish you did it sooner. I'm not afraid to speak up, you know who I am. I know you read this board.
The best thing BioCurex could do at this point would be to have a follow up press release tomorrow or sometime this week. They need to give us some guidance and fill in some of the blanks. We all know why they waited until last week, but now would be an ideal time to learn from their previous mistakes and have some follow thru. I hope they shock us all and hit the ground running in 2008. You can be sure everyone on this board will continue to do our part.
2 links everyone should be checking daily. Open these and send a link to your desktop
http://www.sec.gov/
http://www.fda.gov/search.html
Keep an eye out for clinical trials with Abbott and Inverness Medical
1)Recaf (probably for lung cancer first)
2)Point of care cancer blood test
We will know before the media if we all stay on top of this.
When you see it make your plans for early retirement.
Good luck to all!
I can't get inside his head, but as I was alluding to earlier he had envisioned 3 parts to this company. It would seem more feasible that (like Abbott attempted to do last year) sell off its diagnostic portion of the company. We will have a revenue stream with NO OVERHEAD. It is hard to give that up. This is a worldwide test. Like you said, though, money does talk.
He won't sell. There are 41 million shares outstanding, about 4o million in warrants and options. The total which can be eventually sold and traded is 125 miilion. Is that a enough of a poison pill, probably?
Realistically, the offer would be rediculously low when we don't have earnings to base a P/E on. You guys can have fun tossing this around, but IMO I don't see it.
Why is it so important to qibble over 1 or 2 pennies when they are buying or selling when they buying such small blocks of shares. What I can see happening is a major biotech company offering to buy millions of shares at a premium when it catches wind about what the technology holds for the future. This would probably be acceptable to Dr Moro, however, as I stated earlier, he will not sell the entire company. He has worked his whole life toward this goal and he will see it thru. I have spoken with him in the past and he is very passionate about Recaf. He needs to be at more presentations to keep expanding on all of his latest research. This will be considered a "Best of breed" company, because we have the "best of breed" scientific board.
Bob, that is exactly why anyone selling at these levels will feel pain and regret. IMO, after this week we are ready to break out. If we get one more positive press release it is a slam dunk. How high we actually go is anyone's guess , but the concensus is that we are all feeling pretty good after this week.
We were never on the nasdaq. You need at least 3 million in revenue and the share price cannot be below 1 dollar. We'll be eligible sometime this year. That is a goal of Dr Moro's.
I think we will sign another licensee by next month or hopefully sooner. Everyone forgets that we had more than one deal on the table. There is alot to be excited about. We still aren't considered "for real" until we see some revenue. The groundwork and the infrastructure have been laid and now we can finally start to see the formation of a what will become one of the fastest growing biotech companies in the world. Dr Moro must continue to tweek our current patents and defend our already approved patents. I tried to call Terry on Wednesday and understandably he was too busy to return the call. My questions were about companies now "using" our Recaf receptor to find a cure. Do we have any affiliation with these companies? Is Dr Moro and his attorneys aware of this? Do our patents protect us from someone else capitalizing on our discovery? What is the status with Goshen? Will he approach GE about imaging? Is Wittenberg pulling any teeth today?
I am guilty of buying at the ask multiple times (not this week) to keep us treading water. I feel the same way as you. I realized the share price can appreciate or be kept from depreciating sometimes 10% by buying at the ask no matter if it was 100 shares or a 1000 shares. Remember I said I have been adding to my shares which actually lowered my cost basis over the past 4 years. I am content knowing this was not too good to be true as far as the science goes and I seriously have enough knowledge about the company that we will absolutely succeed. IMO, this is a screaming buy. Anyone selling will be telling the story we all have heard or experienced ourselves about the time I coulda, woulda, shoulda. I am excited about each day now that we are validated once again. It was like we were labeled doomed for failure or a scam. But over and over Dr Moro continues to silence the nay sayers. This is how many companies become household names. Once we have a product launched, which now will be in hyperdrive thanks to our newest(but not last)licensee. It will cause any other potential licensees (and I hear there are many playing with Recaf now) that will feel that they are missing out on a monster money maker. They won't want to be the last ship to leave port.
I can't help being frustrated with the share price, but if we close up 10% a day I shouldn't bit*h. This is and will continue to be volatile till BioCurex launches its Recaf. I wonder if Abbott is sneaky enough to launch outside the US? We have all been fixated on the US and they are a multinational company. They could be sly enough to get european approval first. That way when anyone is searching the databases for any filings we would be looking up the wrong tree. That would be sweet! I doubt it, but you never know.
They keep dropping the ask chasing the bid lower when it should be other way around. It makes it appear as though there is desperation to sell at any cost. This is making it hard for anyone to see the real potential of what we have and will continue to achieve. We have over the last week already covered over 1 million shares. We only have 41 million in the float.